Pol Polyprotein – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Pol Polyprotein – Pipeline Review, H2 2016’, provides in depth analysis on Pol Polyprotein targeted pipeline therapeutics.

The report provides comprehensive information on the Pol Polyprotein, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Pol Polyprotein targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Pol Polyprotein

The report reviews Pol Polyprotein targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Pol Polyprotein targeted therapeutics and enlists all their major and minor projects

The report assesses Pol Polyprotein targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Pol Polyprotein targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Pol Polyprotein

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pol Polyprotein development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

GeoVax Labs, Inc.

Inovio Pharmaceuticals, Inc.

Johnson & Johnson

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Pol Polyprotein Overview 6

Therapeutics Development 7

Pol Polyprotein - Products under Development by Stage of Development 7

Pol Polyprotein - Products under Development by Therapy Area 8

Pol Polyprotein - Products under Development by Indication 9

Pol Polyprotein - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Pol Polyprotein - Products under Development by Companies 12

Pol Polyprotein - Products under Development by Universities/Institutes 14

Pol Polyprotein - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Pol Polyprotein - Companies Involved in Therapeutics Development 21

GeoVax Labs, Inc. 21

Inovio Pharmaceuticals, Inc. 22

Johnson & Johnson 23

Pol Polyprotein - Drug Profiles 24

GOVXB-11 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

GOVXC-11 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

GOVXC-21 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

HIV [serotype Ad26] (tetravalent) vaccine - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

HIV-1 (bivalent) vaccine - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

HIV-1 vaccine 11 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

HIV-1 vaccine 5 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

MVATG-17401 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

PENNVAX-B - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

PENNVAX-GP - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Pol Polyprotein - Dormant Projects 40

Pol Polyprotein - Featured News & Press Releases 41

Oct 20, 2016: GeoVax HIV Vaccine Clinical Data Presented at HIVR4P Conference 41

Aug 02, 2016: GeoVax Awarded NIH Contract for up to $7.8 Million to Manufacture HIV Vaccine for Advanced Human Clinical Trials 41

Jul 14, 2016: Inovio Deploys DNA-based Monoclonal Antibody Technology in Quest to Cure HIV 42

Jun 30, 2016: GeoVax Announces Filing of Investigational New Drug Application for HIV Human Clinical Trial 43

May 18, 2016: GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 43

Apr 14, 2016: GeoVax Awarded $1.4M NIH Grant 44

Mar 07, 2016: Strong Protection Elicited by an Immunodeficiency Virus Vaccine in Non-Human Primates 45

Sep 08, 2015: Inovio Pharmaceuticals Announces First Patient Dosed With Universal HIV Vaccine 45

Apr 14, 2015: GeoVax to Seek Dual Pathway for Advancing Its HIV Preventive Vaccine 46

Apr 09, 2015: GeoVax Provides Details of Presentation at World Vaccine Congress 47

Apr 01, 2015: GeoVax Provides Update on Its HIV Vaccine Program 48

Mar 16, 2015: Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National Institute of Allergy and Infectious Diseases 49

Jan 06, 2015: Inovio Pharmaceuticals HIV Immunotherapy Shows Characteristics Considered Vital to Treating HIV 49

Oct 29, 2014: GeoVax Presents HIV Vaccine Clinical Trial Data 50

Jul 30, 2014: GeoVax Awarded Small Business Innovative Research (SBIR) Grant from National Institutes of Health 51

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by GeoVax Labs, Inc., H2 2016 21

Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 22

Pipeline by Johnson & Johnson, H2 2016 23

Dormant Projects, H2 2016 40

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Routes of Administration, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared